KEYWORDS
Introduction
Zonisamide has been used in the treatment of epilepsy in Japan since it was first marketed in 1989 under the trade name of Excegran ® . We wish to present the current status of zonisamide in Japan, especially with regard to efficacy of this drug, from two perspectives. One is from postmarketing prospective study data, and the other is from our experience in the Department of Neuropsychiatry at Saitama Medical School. 
Postmarketing study Objectives and methods
In order to assess the efficacy and safety of long-term administration of zonisamide, patients with partial and generalized epilepsy were enrolled in a postmarketing prospective study and observed for 1-3 years. Newly diagnosed patients most often received zonisamide as monotherapy. When zonisamide was added to therapy with other antiepilepsy drugs (AEDs), the dosage of the other AEDs was reduced if seizures ceased. Doses in pediatric patients ranged from less than 2 mg/kg per day to more than 10 mg/kg per day, and about 70% S42 T. Yamauchi, H. Aikawa of patients were given zonisamide at 2-8 mg/kg per day. Doses in adults varied from less than 100 mg/day to more than 500 mg/day, and about 80% of patients received 200-400 mg/day. Evaluations were performed by the physicians of 23 survey research groups and by other individually participating physicians. Patient observations and examinations were carried out at the first, second, and the third years of zonisamide administration according to a predetermined schedule depicted in Table 1 .
Discontinuation
The efficacy of zonisamide was analyzed with 1239 patients. At the end of their first year of zonisamide therapy, 1184 patients completed questionnaires. The following year, 680 questionnaires were collected from patients who continued to receive zonisamide. Three hundred ninety-two questionnaires were completed by patients who received zonisamide for more than 2 years (Table 2 ). There were differences in numbers between patients analyzed and patients who presented first-year questionnaires because 55 of the 680 patients who received zonisamide for more than 1 year did not submit their first-year questionnaires. There was a 16.2% discontinuation rate during the first year. Reasons cited included insufficient therapeutic effect (8.7%), side effects (6.2%), or both (1.4%). However, in the second year the discontinuation rate decreased to 7.2%, and in the third year it was 2.3%. These results demonstrate that zonisamide efficacy becomes evident at an early stage of treatment. Only patients responding to zonisamide treatment were continued on the drug. Furthermore, zonisamide efficacy was often associated with a low occurrence of side effects, indicating the possibility of continuous, long-term administration. 
Zonisamide efficacy by seizure type
As shown in Table 3 , partial seizures were completely suppressed in 43.4% of 1172 patients, and efficacy was improved or better in 70.5% of the patients. Improved rates were similar among patients with simple partial seizures, complex partial seizures, and secondarily generalized seizures (data not shown). Among 274 patients with generalized seizures, 122 were classified with tonic-clonic seizures, 128 with tonic seizures, and 24 with clonic seizures. Overall within this group, seizures were improved or better than improved in 56.9% of the patients (data not shown). Although zonisamide was less efficacious in treating generalized seizures than partial seizures, this efficacy was still high.
On the other hand, patients with myoclonic seizures had a seizure-free rate of 19.6%, with 51.8% rated as improved or better. Efficacy against atonic seizures was rated as improved or better 
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Patient background Age
Overall improvement according to patient age is shown in Table 5 . Patients were grouped as ≤1, 2-15, and ≥16 years of age. Improvement rates were similar across all age groups.
Interaction of AED therapy and seizure type
Effects of zonisamide were analyzed by seizure type and also by the type of zonisamide therapy (monotherapy or polytherapy; Table 6 ). The zonisamide monotherapy group had a significantly higher improvement rate (defined as greater than or equal to 50% reduction in seizure frequency) than did the polytherapy group (P < 0.01). However, there was no difference in the improvement rates between patients with partial seizures and patients with generalized seizures. As patients who received polytherapy, and those intractable to treatments, are considered to have strong epileptogenesis, the findings suggest that seizures produced by strong epileptogenesis were poorly controlled, even with combinations of zonisamide and other AEDs. This suggests that a high improvement rate can be anticipated when zonisamide is the first choice of drug to use.
Postmarketing study conclusions
From the postmarketing survey for long-term treatment, the following conclusions were obtained: 
Efficacy of zonisamide based on our experiences in the Department of Neuropsychiatry at Saitama Medical School
To understand how zonisamide is used for the treatment of patients with epilepsy, we have examined numerous patients who were treated with zonisamide in the Department of Neuropsychiatry at the Saitama Medical School. We carried out a retrospective study and analysis based on data collected in October 1998, from 60 outpatients being treated with zonisamide.
Patient background
Age, sex, duration of epilepsy The study included 30 male and 30 female patients. Ages of the 60 patients in the cohort ranged from 15 to 73 years (mean = 36.5 ± 14.8). Age at epilepsy onset was 3-68 years (mean = 19.8 ± 13.8), and duration of epilepsy was 1-57 years (mean = 17.5 ± 12.8). In summary, our patients represented a wide range in terms of age, age of epilepsy onset, and duration of epilepsy.
Seizure type
Fifty-three patients had partial seizures (88.3%), five had tonic-clonic seizures (8.3%), and two had myoclonic seizures (3.3%). Of the patients with partial seizures, 14 had simple partial seizures (26.4%) and 39 had complex partial seizures (73.6%).
Dosage and administration of zonisamide
Ten patients were treated with zonisamide monotherapy. The remaining 50 patients were treated with zonisamide in combination with other AEDs, such as valproic acid (57.8%), phenytoin (6%), carbamazepine (51.1%), phenobarbital (31%), clonazepam (26.7%), or other drugs (6.6%). Among those patients taking zonisamide alone, the average dose of zonisamide was 250 ± 52.7 mg (range (5) 60 (3) 0 40 (2) Myoclonic (2) 0 50 (1) 50 (1) Total (56) 50 (28) 30.4 (17) 19.6 (11) 200-300 mg). Among patients taking zonisamide in combination with other AEDs, the average dose of zonisamide was notably higher, 286 ± 108.8 mg (range 100-600 mg).
Effect of zonisamide on seizures
Rate of seizure improvement according to seizure type The efficacy of zonisamide was not evaluable in four patients because they had already been treated with zonisamide when they were referred to our clinic and their seizures had stopped. These patients were excluded. Among the remaining 56 patients analyzed in this study, 49 had partial seizures, five had tonic-clonic seizures, and two had myoclonic seizures (Table 7) . Fifty percent (28 patients) were seizure free or showed marked improvement, 30.4% (17 patients) showed improvement (50-75% decrease in seizures), and 19.6% (11 patients) showed no change. These seizure control rates largely reflect improvement among partial seizure patients, who made up the largest percentage of the group. However, three out of five patients with tonic-clonic showed marked improvement. Of the two patients with myoclonic seizures, one improved and one showed no change. Furthermore, although we investigated patients with simple and complex partial seizures, both with or without secondary generalization, we found no evidence of significant differences in seizure reduction based on the seizure type.
Relationship between efficacy and the number of AEDs
The seizure control rate was higher among those patients using zonisamide alone (88.9% markedly improved, 11.1% improved, 0% no effect) compared with the group using zonisamide in combination with other AEDs (42.6% markedly improved, 34.0% improved, 23.4% no effect; P < 0.05). Since we found lower efficacy in the polytherapy group, we investigated the relationship between zonisamide efficacy and the number of concomitant AEDs. The results from this analysis, shown in Table 8 , demonstrate that seizure control drops as the number of AEDs increases. These findings suggest that further investigation is needed to understand relationships between zonisamide dosage, the number of concomitant drugs, and zonisamide efficacy.
Number of concomitant AEDs and zonisamide efficacy
The number of concomitant AEDs used to treat patients in each efficacy group was examined. Markedly improved patients were treated with an average of 1.2 AEDs; patients in the improved group, 2.0 AEDs; and patients in the unchanged group, 2.4 AEDs. This analysis shows that the patients in the unchanged group were taking more AEDs compared to the other groups.
Zonisamide dosage and efficacy
Relationships between the dose of zonisamide and its effect on seizure rate were examined. We found that the dosage of zonisamide was significantly greater for the improvement group (347 ± 100.7 mg), compared to the patients in the markedly improved (250 ± 79.3 mg) or unchanged (254.5 ± 121.4 mg) groups. These findings suggest that in responsive patients, most likely those with relatively weak epileptogenesis, seizures can be controlled by low doses of zonisamide. In our study, this type of patient who showed marked response to zonisamide was encountered in 28 of 56 cases (50%).
Relationship between plasma concentration and administered zonisamide dose
We hypothesized that poor seizure control at high doses of zonisamide may result from poor absorption. To confirm this hypothesis, we investigated the relationship between administered dose and plasma concentration of zonisamide. We found that zonisamide concentration increased dose-dependently ( Fig. 1) .
Relationship between plasma concentration of zonisamide and number of AEDs
We then investigated the relationship between the ratio of plasma concentration to the administered dose of zonisamide and number of concomitant AEDs (Fig. 2) . The ratio of plasma concentration to administered dose decreased with increasing numbers of concomitant AEDs.
Effect of other AEDs on plasma concentration of zonisamide
We next examined the relationship between individual concomitant AEDs and the ratio of plasma concentration to the administered dose of zonisamide (Fig. 3) . Results showed that the ratio is significantly lower when zonisamide is administered with PHT (P < 0.05). It also became evident that carbamazepine, phenobarbital, valproic acid, and clonazepam have no influence upon zonisamide concentration.
Relationship between plasma concentration of zonisamide and efficacy
The relationship between plasma concentration of zonisamide and efficacy was then examined. The eight patients whose seizures were unaffected by zonisamide treatment had significantly lower plasma concentrations of zonisamide (10.2 ± 8 g/mL), compared with the 14 patients whose seizures improved (19.0 ± 6.1 g/mL), or the 20 patients whose seizures markedly improved (17.6 ± 6.6 g/mL; P < 0.05 and 0.05, respectively). 
Patients unaffected by zonisamide treatment
From the above investigation, it was evident that dosage and plasma concentration of zonisamide were low in those patients whose seizures were unaffected by zonisamide treatment. Several explanations may apply:
1. Low plasma concentrations of zonisamide may be insufficient to suppress epileptic seizures. 2. Combined administrations of several AEDs with zonisamide might decrease the plasma concentration of zonisamide. 3. Patients in this group have strong epileptogenesis; therefore seizures may not be suppressed even by AED polytherapy.
Characteristics of three patient groups
From the data reported here, patients could be categorized into three groups: 
